TY  - GEN
AU  - García-García, María Luz
AU  - Alonso-López, Patricia
AU  - Alcolea, Sonia
AU  - Arroyas, M
AU  - Pozo Sanchez, Francisco
AU  - Casas Flecha, Inmaculada
AU  - Iglesias-Caballero, Maria
AU  - Sánchez-León, Rocío
AU  - Hurtado-Gallego, Jara
AU  - Calvo, Cristina
PY  - 2025
DO  - 10.1111/irv.70105
UR  - https://hdl.handle.net/20.500.12105/27710
AB  - Background: Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare the...
LA  - eng
PB  - Wiley
KW  - Bronchiolitis
KW  - Nirsevimab
KW  - Respiratory infections
KW  - Respiratory syncytial virus
KW  - Antibodies, Monoclonal, Humanized
KW  - Antiviral Agents
KW  - Female
KW  - Hospitalization
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Male
KW  - Prospective Studies
KW  - Respiratory Syncytial Virus Infections
KW  - Respiratory Syncytial Virus, Human
KW  - Respiratory Tract Infections
KW  - Spain
TI  - Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants.
TY  - research article
ER  -